por
Barbara Kram, Editor | October 15, 2008
iCAD's motto is
"Never Stop Looking"
Nashua, NH - iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, will unveil two new MRI products at the 7th Annual Symposium on Advances in Breast MRI in Las Vegas, from October 16-18: SpectraLook™, innovative kinetics technology integrated into iCAD's image analysis solutions for breast and prostate MRI studies; and CADvue™, image review and analysis software designed to improve the analysis workflow, interventional planning and reporting of breast MR results.
"These two new products are the result of leading edge research and development using kinetics technology." said Ken Ferry, President and CEO of iCAD. "We are very excited to expand into this new market offering the most comprehensive detection solutions for breast care and workflow."
SpectraLook™, iCAD's breast MR analysis solution, provides more diagnostic information by creating colorized images based on signal changes defined by tumor physiology. iCAD's All Time Point (ATP) analysis is based on an advanced pharmacokinetic model that calculates numerical values of key physiological parameters, allowing the user to detect the different biological processes taking place in malignant versus benign tumors. These key physiological markers can aid in the analysis of large MR datasets.

Ad Statistics
Times Displayed: 19605
Times Visited: 366 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
CADvue™ image review and analysis software provides maximum functionality facilitating the analysis of ATP colorized images and quantitative data. CADvue allows the user to create standard and customized reports that enable the user to communicate time-sensitive breast MR study results to referring physicians. The reports provide detailed and comprehensive information that is critical to the identification and analysis of abnormalities. 3D colorized images within the report assist clinicians to effectively communicate options to their patients.
"Our SpectraLook and CADvue products will significantly help streamline the radiologist's workflow and the diagnosis process," said Ferry. "Radiologists can look at images easily and quickly, while reducing operating costs and increasing effectiveness of patient care."
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Currently available in more than 2,200 healthcare centers worldwide, iCAD's solutions aid in the early detection of the most prevalent cancers including breast, colon, prostate and in the future, lung cancer. For more information, visit www.icadmed.com.